Post Categories
EU Clinical Trial Regulation 536/2014 and CTIS: Common Questions and Answers
As reported in our previous CTIS-related blog post, the way clinical trials are documented in the European Union (EU) is changing. By January 31,…
EU Clinical Trial Regulation 536/2014 and CTIS: Common Questions and Answers
March 20, 2024
As reported in our previous CTIS-related blog post, the way clinical trials are documented in the European Union (EU) is changing. By January 31,…
Customized Therapies Offer Hope for Patients with Ultra-Rare Genetic Diseases
Leveraging rapid developments in gene therapy, researchers are designing new ways to target ultra-rare genetic diseases with treatments tailored to a patient’s specific genetic…
Customized Therapies Offer Hope for Patients with Ultra-Rare Genetic Diseases
March 18, 2024
Leveraging rapid developments in gene therapy, researchers are designing new ways to target ultra-rare genetic diseases with treatments tailored to a patient’s specific genetic…
Navigating Changes to EU Clinical Trial Management: What You Need to Know
The face of clinical trials in the European Union (EU) is changing. By January 31, 2025, all ongoing clinical trials must move to the…
Navigating Changes to EU Clinical Trial Management: What You Need to Know
March 13, 2024
The face of clinical trials in the European Union (EU) is changing. By January 31, 2025, all ongoing clinical trials must move to the…
Psychoactive Drug Ibogaine Has Transformative Effects for Veterans with Traumatic Brain Injury
Traumatic brain injuries (TBIs), commonly experienced by military personnel, often incur deep damage and invisible scars. Such injuries are significant contributors to post-traumatic stress…
Psychoactive Drug Ibogaine Has Transformative Effects for Veterans with Traumatic Brain Injury
March 11, 2024
Traumatic brain injuries (TBIs), commonly experienced by military personnel, often incur deep damage and invisible scars. Such injuries are significant contributors to post-traumatic stress…
The Link Between Obesity Drugs and Brain Health
Glucagon-like peptide-1 (GLP-1) receptor agonists are arguably the hottest topic in medical innovation. The drugs semaglutide and tirzepatide, known under brand names like Ozempic,…
The Link Between Obesity Drugs and Brain Health
March 6, 2024
Glucagon-like peptide-1 (GLP-1) receptor agonists are arguably the hottest topic in medical innovation. The drugs semaglutide and tirzepatide, known under brand names like Ozempic,…
Advances in Treating Autoimmune Diseases Focus on Restoring Immune Tolerance
For decades, the battle against autoimmune diseases like type 1 diabetes, lupus, and multiple sclerosis has been an uphill struggle. Conventional treatments most often…
Advances in Treating Autoimmune Diseases Focus on Restoring Immune Tolerance
March 4, 2024
For decades, the battle against autoimmune diseases like type 1 diabetes, lupus, and multiple sclerosis has been an uphill struggle. Conventional treatments most often…
Research Challenges Conventional Wisdom on Obesity and Mortality
Research using data from a large U.S. health survey has disrupted conventional thinking about body mass index (BMI) and its role in predicting all-cause…
Research Challenges Conventional Wisdom on Obesity and Mortality
February 26, 2024
Research using data from a large U.S. health survey has disrupted conventional thinking about body mass index (BMI) and its role in predicting all-cause…
Fighting Disease Transmission From Humans to Chimpanzees: A Critical Conservation Effort
When a human virus was identified as the source of a 2017 respiratory disease outbreak among chimps at Uganda’s Kibale National Park, the discovery…
Fighting Disease Transmission From Humans to Chimpanzees: A Critical Conservation Effort
February 19, 2024
When a human virus was identified as the source of a 2017 respiratory disease outbreak among chimps at Uganda’s Kibale National Park, the discovery…
Could Newly Identified Genetic Variant Hold the Key to Metabolic Health?
Lurking among the vast genetic holdings of the UK Biobank data, researchers uncovered a potential gem — a gene variant linked to cardiometabolic health….
Could Newly Identified Genetic Variant Hold the Key to Metabolic Health?
February 14, 2024
Lurking among the vast genetic holdings of the UK Biobank data, researchers uncovered a potential gem — a gene variant linked to cardiometabolic health….
“It’s Incredible” — Breakthrough Spinal Implant Restores Walking Ability Lost Due to Parkinson’s Disease
Marc, a 63-year-old from Bordeaux, France, has lived with Parkinson’s disease for more than two decades. The disease had increasingly hindered his mobility, causing…
“It’s Incredible” — Breakthrough Spinal Implant Restores Walking Ability Lost Due to Parkinson’s Disease
February 12, 2024
Marc, a 63-year-old from Bordeaux, France, has lived with Parkinson’s disease for more than two decades. The disease had increasingly hindered his mobility, causing…
“Like Day and Night” — CRISPR’s Life-Changing Potential in Sickle Cell Disease
A groundbreaking gene editing therapy for sickle cell disease from CRISPR Therapeutics and Vertex Pharmaceuticals has received approval from the U.S. Food and Drug…
“Like Day and Night” — CRISPR’s Life-Changing Potential in Sickle Cell Disease
February 5, 2024
A groundbreaking gene editing therapy for sickle cell disease from CRISPR Therapeutics and Vertex Pharmaceuticals has received approval from the U.S. Food and Drug…
Pharma’s Expanding Arsenal Against Mosquitoes — the World’s Deadliest Creatures
Although mosquitoes measure less than an inch and weigh a mere 2.5 milligrams, the disease burdens they carry make them the “deadliest animal on…
Pharma’s Expanding Arsenal Against Mosquitoes — the World’s Deadliest Creatures
January 29, 2024
Although mosquitoes measure less than an inch and weigh a mere 2.5 milligrams, the disease burdens they carry make them the “deadliest animal on…
EU Clinical Trial Regulation 536/2014 and CTIS: Common Questions and Answers
As reported in our previous CTIS-related blog post, the way clinical trials are documented in the European Union (EU) is changing. By January 31,…
EU Clinical Trial Regulation 536/2014 and CTIS: Common Questions and Answers
March 20, 2024
As reported in our previous CTIS-related blog post, the way clinical trials are documented in the European Union (EU) is changing. By January 31,…
Customized Therapies Offer Hope for Patients with Ultra-Rare Genetic Diseases
Leveraging rapid developments in gene therapy, researchers are designing new ways to target ultra-rare genetic diseases with treatments tailored to a patient’s specific genetic…
Customized Therapies Offer Hope for Patients with Ultra-Rare Genetic Diseases
March 18, 2024
Leveraging rapid developments in gene therapy, researchers are designing new ways to target ultra-rare genetic diseases with treatments tailored to a patient’s specific genetic…
Navigating Changes to EU Clinical Trial Management: What You Need to Know
The face of clinical trials in the European Union (EU) is changing. By January 31, 2025, all ongoing clinical trials must move to the…
Navigating Changes to EU Clinical Trial Management: What You Need to Know
March 13, 2024
The face of clinical trials in the European Union (EU) is changing. By January 31, 2025, all ongoing clinical trials must move to the…
Psychoactive Drug Ibogaine Has Transformative Effects for Veterans with Traumatic Brain Injury
Traumatic brain injuries (TBIs), commonly experienced by military personnel, often incur deep damage and invisible scars. Such injuries are significant contributors to post-traumatic stress…
Psychoactive Drug Ibogaine Has Transformative Effects for Veterans with Traumatic Brain Injury
March 11, 2024
Traumatic brain injuries (TBIs), commonly experienced by military personnel, often incur deep damage and invisible scars. Such injuries are significant contributors to post-traumatic stress…
The Link Between Obesity Drugs and Brain Health
Glucagon-like peptide-1 (GLP-1) receptor agonists are arguably the hottest topic in medical innovation. The drugs semaglutide and tirzepatide, known under brand names like Ozempic,…
The Link Between Obesity Drugs and Brain Health
March 6, 2024
Glucagon-like peptide-1 (GLP-1) receptor agonists are arguably the hottest topic in medical innovation. The drugs semaglutide and tirzepatide, known under brand names like Ozempic,…
Advances in Treating Autoimmune Diseases Focus on Restoring Immune Tolerance
For decades, the battle against autoimmune diseases like type 1 diabetes, lupus, and multiple sclerosis has been an uphill struggle. Conventional treatments most often…
Advances in Treating Autoimmune Diseases Focus on Restoring Immune Tolerance
March 4, 2024
For decades, the battle against autoimmune diseases like type 1 diabetes, lupus, and multiple sclerosis has been an uphill struggle. Conventional treatments most often…
Introduction RNA based drugs are a promising new class of therapeutics with tremendous potential for treating a wide range of diseases. There are various…
About Messenger Ribonucleic Acid (mRNA) Current mRNA (messenger ribonucleic acid) research has rapidly driven the discovery and production of this new therapeutic. Modified mRNAs…
Introduction Development of DNA or RNA analogs that can block the activity of selected genetic sequences makes the design of highly specific therapeutic treatments…
NEWARK, Delaware, January 10, 2024/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials,…
NEWARK, Delaware, Dec. 14, 2023/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials,…
SPRINGFIELD, Missouri, Dec. 4, 2023/BUSINESS WIRE/ — QPS Holdings, LLC, a global contract research organization, has expanded operations in Springfield, Missouri. The new facilities…